FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3093818097> ?p ?o ?g. }

• W3093818097 endingPage "976" @default.
• W3093818097 startingPage "970" @default.
• W3093818097 abstract "Abstract The prevalence of both atrial fibrillation (AF) and obesity has steadily increased. Nonvitamin K antagonist oral anticoagulants (NOACs) have been shown to be more effective and safer than vitamin K antagonists (VKAs) for long-term stroke prevention in patients with nonvalvular AF. There are still limited data in the literature regarding performance of NOACs in obese patients with AF in the “real world.” The aim of our study was to compare the safety and effectiveness of NOACs versus well-controlled VKA therapy in obese AF patients in a “real-world” setting. Here, we have considered patients with AF and obesity (body mass index [BMI] > 30 kg/m2) on NOAC or VKA therapy included in the multicenter Atrial Fibrillation Research Database (NCT03760874). The occurrence of major bleedings (MBs) and thromboembolic events (composite of ischemic stroke, transient ischemic attack, and systemic embolism) was respectively considered primary safety and effectiveness outcomes. We identified 1,047 AF patients with obesity who received NOAC (n = 272) or VKA (n = 775) treatment. After propensity score matching analysis, 248 NOAC and 496 VKA recipients with similar clinical characteristics, including BMI (34.8 ± 3.4 in NOAC vs. 35.1 ± 3.8 in the VKA group; p = 0.50), were evaluated. The mean follow-up was 39 ± 7 months. The incidence rate of thromboembolic events was 1.10 per 100 person-years (0.67 in NOAC vs. 1.28 in the VKA group; hazard ratio [HR]: 0.52; 95% confidence interval [CI]: 0.22–1.22; p = 0.19). The incidence rate of MB was 1.9 per 100 person-years (1.1 in NOAC vs. 2.28 in the VKA group; HR: 0.46; 95% CI: 0.24–0.88; p = 0.04). The incidence rate of intracranial hemorrhage was 0.4 per 100 person-years (0.27 in NOAC vs. 0.47 in the VKA group; HR: 0.57; 95% CI: 0.12–2.73; p = 0.48). A positive net clinical benefit (NCB) of NOACs over VKAs was found (+0.91). Presence of anemia (HR: 1.75; p = 0.003) and concomitant use of antiplatelet drugs (HR: 2.41; p = 0.001) were found to be independent predictors of MB; moreover, age (HR: 1.65; p = 0.003) was an independent predictor of thromboembolic events. Our data support the hypothesis of safe and effective use of NOACs in patients with AF and obesity, justified by a statistically significant lower incidence of MB and a favorable NCB over VKAs." @default.
• W3093818097 created "2020-10-29" @default.
• W3093818097 creator A5003503228 @default.
• W3093818097 creator A5015211243 @default.
• W3093818097 creator A5015966822 @default.
• W3093818097 creator A5024678072 @default.
• W3093818097 creator A5033587549 @default.
• W3093818097 creator A5034394063 @default.
• W3093818097 creator A5049271044 @default.
• W3093818097 creator A5050522038 @default.
• W3093818097 date "2020-10-26" @default.
• W3093818097 modified "2023-10-15" @default.
• W3093818097 title "Clinical Performance of Nonvitamin K Antagonist Oral Anticoagulants in Real-World Obese Patients with Atrial Fibrillation" @default.
• W3093818097 cites W157431864 @default.
• W3093818097 cites W1616673690 @default.
• W3093818097 cites W1826211555 @default.
• W3093818097 cites W1969658718 @default.
• W3093818097 cites W1991638671 @default.
• W3093818097 cites W2005076314 @default.
• W3093818097 cites W2056541539 @default.
• W3093818097 cites W2072779975 @default.
• W3093818097 cites W2096246254 @default.
• W3093818097 cites W2097854437 @default.
• W3093818097 cites W2101688816 @default.
• W3093818097 cites W2109907016 @default.
• W3093818097 cites W2130340163 @default.
• W3093818097 cites W2136489990 @default.
• W3093818097 cites W2144891869 @default.
• W3093818097 cites W2162499932 @default.
• W3093818097 cites W2162508946 @default.
• W3093818097 cites W2311379003 @default.
• W3093818097 cites W2337286163 @default.
• W3093818097 cites W2594312574 @default.
• W3093818097 cites W2597608277 @default.
• W3093818097 cites W2606391344 @default.
• W3093818097 cites W2606507895 @default.
• W3093818097 cites W2761300892 @default.
• W3093818097 cites W2790203393 @default.
• W3093818097 cites W2821786565 @default.
• W3093818097 cites W2888594054 @default.
• W3093818097 cites W2889229861 @default.
• W3093818097 cites W2946668006 @default.
• W3093818097 doi "https://doi.org/10.1055/s-0040-1715792" @default.
• W3093818097 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33105504" @default.
• W3093818097 hasPublicationYear "2020" @default.
• W3093818097 type Work @default.
• W3093818097 sameAs 3093818097 @default.
• W3093818097 citedByCount "11" @default.
• W3093818097 countsByYear W30938180972016 @default.
• W3093818097 countsByYear W30938180972020 @default.
• W3093818097 countsByYear W30938180972021 @default.
• W3093818097 countsByYear W30938180972022 @default.
• W3093818097 countsByYear W30938180972023 @default.
• W3093818097 crossrefType "journal-article" @default.
• W3093818097 hasAuthorship W3093818097A5003503228 @default.
• W3093818097 hasAuthorship W3093818097A5015211243 @default.
• W3093818097 hasAuthorship W3093818097A5015966822 @default.
• W3093818097 hasAuthorship W3093818097A5024678072 @default.
• W3093818097 hasAuthorship W3093818097A5033587549 @default.
• W3093818097 hasAuthorship W3093818097A5034394063 @default.
• W3093818097 hasAuthorship W3093818097A5049271044 @default.
• W3093818097 hasAuthorship W3093818097A5050522038 @default.
• W3093818097 hasConcept C120665830 @default.
• W3093818097 hasConcept C121332964 @default.
• W3093818097 hasConcept C126322002 @default.
• W3093818097 hasConcept C127413603 @default.
• W3093818097 hasConcept C164705383 @default.
• W3093818097 hasConcept C207103383 @default.
• W3093818097 hasConcept C2776301958 @default.
• W3093818097 hasConcept C2776704044 @default.
• W3093818097 hasConcept C2779161974 @default.
• W3093818097 hasConcept C2780221984 @default.
• W3093818097 hasConcept C2780645631 @default.
• W3093818097 hasConcept C44249647 @default.
• W3093818097 hasConcept C61511704 @default.
• W3093818097 hasConcept C71924100 @default.
• W3093818097 hasConcept C78519656 @default.
• W3093818097 hasConceptScore W3093818097C120665830 @default.
• W3093818097 hasConceptScore W3093818097C121332964 @default.
• W3093818097 hasConceptScore W3093818097C126322002 @default.
• W3093818097 hasConceptScore W3093818097C127413603 @default.
• W3093818097 hasConceptScore W3093818097C164705383 @default.
• W3093818097 hasConceptScore W3093818097C207103383 @default.
• W3093818097 hasConceptScore W3093818097C2776301958 @default.
• W3093818097 hasConceptScore W3093818097C2776704044 @default.
• W3093818097 hasConceptScore W3093818097C2779161974 @default.
• W3093818097 hasConceptScore W3093818097C2780221984 @default.
• W3093818097 hasConceptScore W3093818097C2780645631 @default.
• W3093818097 hasConceptScore W3093818097C44249647 @default.
• W3093818097 hasConceptScore W3093818097C61511704 @default.
• W3093818097 hasConceptScore W3093818097C71924100 @default.
• W3093818097 hasConceptScore W3093818097C78519656 @default.
• W3093818097 hasIssue "08" @default.
• W3093818097 hasLocation W30938180971 @default.
• W3093818097 hasOpenAccess W3093818097 @default.
• W3093818097 hasPrimaryLocation W30938180971 @default.
• W3093818097 hasRelatedWork W1997300706 @default.
• W3093818097 hasRelatedWork W2047263140 @default.

• next